Kezar Life Sciences KZR Stock
Kezar Life Sciences Price Chart
Kezar Life Sciences KZR Financial and Trading Overview
| Kezar Life Sciences stock price | 0.81 USD |
| Previous Close | 2.6 USD |
| Open | 2.6 USD |
| Bid | 0 USD x 2200 |
| Ask | 0 USD x 1800 |
| Day's Range | 2.37 - 2.69 USD |
| 52 Week Range | 2.25 - 11.02 USD |
| Volume | 1.07M USD |
| Avg. Volume | 1.05M USD |
| Market Cap | 191.16M USD |
| Beta (5Y Monthly) | 0.161011 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.5 USD |
KZR Valuation Measures
| Enterprise Value | -45797952 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.9555556 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.740533 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.58 |
Trading Information
Kezar Life Sciences Stock Price History
| Beta (5Y Monthly) | 0.161011 |
| 52-Week Change | -50.094% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 11.02 USD |
| 52 Week Low | 2.25 USD |
| 50-Day Moving Average | 2.63 USD |
| 200-Day Moving Average | 5.87 USD |
KZR Share Statistics
| Avg. Volume (3 month) | 1.05M USD |
| Avg. Daily Volume (10-Days) | 909.17K USD |
| Shares Outstanding | 72.41M |
| Float | 35.8M |
| Short Ratio | 3.59 |
| % Held by Insiders | 20.22% |
| % Held by Institutions | 86.03% |
| Shares Short | 2.87M |
| Short % of Float | 4.09% |
| Short % of Shares Outstanding | 3.96% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -18.60% |
| Return on Equity (ttm) | -30.69% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -78943000 USD |
| Net Income Avi to Common (ttm) | -74414000 USD |
| Diluted EPS (ttm) | -1.05 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 257.67M USD |
| Total Cash Per Share (mrq) | 3.56 USD |
| Total Debt (mrq) | 20.72M USD |
| Total Debt/Equity (mrq) | 8.21 USD |
| Current Ratio (mrq) | 19.44 |
| Book Value Per Share (mrq) | 3.565 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -66392000 USD |
| Levered Free Cash Flow (ttm) | -34810124 USD |
Profile of Kezar Life Sciences
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 4000 Shoreline Court |
| ZIP | 94080 |
| Phone | (650) 822-5600 |
| Website | https://www.kezarlifesciences.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 84 |
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Q&A For Kezar Life Sciences Stock
What is a current KZR stock price?
Kezar Life Sciences KZR stock price today per share is 0.81 USD.
How to purchase Kezar Life Sciences stock?
You can buy KZR shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kezar Life Sciences?
The stock symbol or ticker of Kezar Life Sciences is KZR.
Which industry does the Kezar Life Sciences company belong to?
The Kezar Life Sciences industry is Biotechnology.
How many shares does Kezar Life Sciences have in circulation?
The max supply of Kezar Life Sciences shares is 77.54M.
What is Kezar Life Sciences Price to Earnings Ratio (PE Ratio)?
Kezar Life Sciences PE Ratio is now.
What was Kezar Life Sciences earnings per share over the trailing 12 months (TTM)?
Kezar Life Sciences EPS is -1.4 USD over the trailing 12 months.
Which sector does the Kezar Life Sciences company belong to?
The Kezar Life Sciences sector is Healthcare.
Kezar Life Sciences KZR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}